Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Obesity-Drug Makers Stop Getting Bullied

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Even bullies can have a change of heart.

When it comes to obesity drugs, there's really no better way to describe the Food and Drug Administration recently than as a bully. Over the course of four months, the agency tormented obesity-drug makers with three separate rejections -- VIVUS' (Nasdaq: VVUS  ) Qnexa, Arena Pharmaceuticals' (Nasdaq: ARNA  ) lorcaserin, and Orexigen's (Nasdaq: OREX  ) Contrave -- and pulled a fourth -- Abbott Labs' (NYSE: ABT  ) Merida --- off the market. Then the agency bullied the rejected biotechs a little more, increasing the list of things they had to do to get their drugs approved, which includes conducting unrealistic clinical trials.

But the agency seems to be having a change of heart. Rather than treat obesity treatments as lifestyle drugs that need a perfect bill of health on the safety side to gain approval, the agency seems to be acting somewhat reasonably -- at least according to the companies.

Last week, VIVUS said it had reached an agreement with the FDA to allow it to apply for approval in just men and women without child-bearing potential while it waits for data on whether the drug adversely affects fetuses.

And then yesterday Orexigen said the agency has agreed to a much smaller clinical trial than the 60,000-to-100,000-patient trial the agency had originally asked for. The new trial design will require less than 10,000 patients and could read out in less than two years.

So where does this leave VIVUS, Arena, and Orexigen? While prospects for approval are looking better than they were a few weeks ago, investors certainly aren't convinced that the chance of an FDA approval is as high as it was before the rejections.


2010 High

Opening Price Today






Arena Pharmaceuticals








Source: Yahoo! Finance.

That seems about right to me; VIVUS isn't as dependent on Qnexa since it also has an erectile dysfunction drug in the works. There's just not that much to get excited about here. Obesity drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval.

The bully may have seen the light of day, but its targets are still stuck in a locker with their shorts pulled over their heads.

Interested in keeping track of the obesity drugs as they make a second attempt at approval? Add them to the Fool's free My Watchlist service to keep track of all our Foolish coverage of the companies.

Download our special free report "5 Stocks The Motley Fool Owns -- And You Should Too" and see which companies top Motley Fool analysts hand-selected for a real-money portfolio.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1557308, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:18:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,204.02 4.69 0.03%
S&P 500 2,136.29 -3.14 -0.15%
NASD 5,226.44 -23.83 -0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 2:59 PM
OREX $3.00 Down -0.04 -1.28%
Orexigen Therapeut… CAPS Rating: *
ABT $40.30 Up +0.34 +0.85%
Abbott Laboratorie… CAPS Rating: *****
ARNA $1.58 Down -0.01 -0.63%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.12 Down +0.00 +0.00%
VIVUS CAPS Rating: **